[Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis]

Med Clin (Barc). 2015 Feb 20;144(4):190-1. doi: 10.1016/j.medcli.2014.05.020. Epub 2014 Jul 9.

[Article in Spanish]

Authors

Isabel Delgado Pecellín¹, Esther Quintana Gallego², Celeste Pedregal Solano², Carmen Calero Acuña²

Affiliations

¹ Unidad de Fibrosis Quística, Hospital Virgen del Rocío, Sevilla, España. Electronic address: [email protected].
² Unidad de Fibrosis Quística, Hospital Virgen del Rocío, Sevilla, España.

PMID: 25015245
DOI: 10.1016/j.medcli.2014.05.020

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Adult
Antibodies, Anti-Idiotypic / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antifungal Agents / therapeutic use
Aspergillosis, Allergic Bronchopulmonary / diagnostic imaging
Aspergillosis, Allergic Bronchopulmonary / drug therapy*
Aspergillosis, Allergic Bronchopulmonary / etiology
Cystic Fibrosis / complications*
Drug Therapy, Combination
Female
Humans
Immunoglobulin E / immunology
Male
Omalizumab
Prednisone / therapeutic use
Tomography, X-Ray Computed

Substances

Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized
Antifungal Agents
Omalizumab
Immunoglobulin E
Prednisone